The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CDTX | +734.41% | +53.66% | +8.96% | -71% |
| S&P | +16.9% | +95.99% | +14.39% | +222% |
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
The company earned an important fast-track review designation for a pipeline medication.
The company could have quite a winner on its hands with its most advanced pipeline drug.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.03M | -111.0% |
| Gross Margin | 81.13% | 0.0% |
| Market Cap | $631.76M | 1059.9% |
| Market Cap / Employee | $16.63M | 0.0% |
| Employees | 38 | -44.9% |
| Net Income | -$25.72M | 72.7% |
| EBITDA | -$31.29M | -183.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $516.91M | 214.5% |
| Accounts Receivable | $1.86M | -20.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.84M | -69.9% |
| Short Term Debt | $1.50M | -1.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -33.09% | 65.0% |
| Return On Invested Capital | -42.67% | 9.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$40.96M | 60.5% |
| Operating Free Cash Flow | -$40.96M | 60.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.38 | 1.64 | 1.44 | 4.20 | -237.02% |
| Price to Sales | 1.39 | 2.66 | 29.83 | 1011.22 | 56068.96% |
| Price to Tangible Book Value | 0.38 | 1.64 | 1.44 | 4.20 | -237.02% |
| Enterprise Value to EBITDA | 3.07 | -1.27 | -4.35 | -7.76 | -181.14% |
| Return on Equity | -203.3% | -222.4% | -299.6% | -37.1% | -77.09% |
| Total Debt | $3.94M | $3.58M | $2.67M | $2.33M | -45.74% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
